Please confirm you are human

This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.

A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.

Hold with a pointer, or hold Space or Enter.

News

PharmaDispatch
pharmadispatch.com > news > australias-biggest-week-in-biotech-brings-global-life-sciences-leaders-to-the-gold-coast

Australia’s 'Biggest Week in Biotech' brings global life sciences leaders to the Gold Coast

1+ hour, 4+ min ago   (115+ words) PharmaDispatch Australia’s 'Biggest Week in Biotech' brings global life sciences leaders to the Gold Coast AusBiotech has unveiled the integrated program for the 2026 AusBiotech International Conference and AusMedtech Conference, bringing more than 250 speakers together across approximately 60 sessions on the Gold…...

PharmaDispatch
pharmadispatch.com > news > argenx-partners-with-monash-university-and-myostellar-to-develop-muscular-therapies

argenx partners with Monash University and Myostellar to develop muscular therapies

2+ day, 8+ hour ago   (140+ words) PharmaDispatch argenx partners with Monash University and Myostellar to develop muscular therapies Kathryn Evans, General Manager, Australia at argenx, said, “We’re very pleased to further strengthen argenx’s relationship with Monash through the new research collaboration, enabling us to access and…...

PharmaDispatch
pharmadispatch.com > news > helping-to-build-australias-life-sciences-future-at-brisbanes-innovation-junction

Helping to build Australia’s life sciences future at Brisbane’s innovation junction

1+ week, 4+ day ago   (146+ words) PharmaDispatch Helping to build Australia’s life sciences future at Brisbane’s innovation junction Professor Trent Munro, General Manager of the BRIJ, and Rebekah Cassidy, CEO of AusBiotech, spoke with BioPharmaDispatch-BPDInsights about the precinct’s contribution to how Australia’s life sciences sector is…...

PharmaDispatch
pharmadispatch.com > news > the-end-of-days-language-is-just-a-farcical-attempt-to-shut-down-discussion

The 'end of days' language is just a farcical attempt to shut down discussion

2+ week, 2+ day ago   (138+ words) PharmaDispatch The 'end of days' language is just a farcical attempt to shut down discussion There is a distinct and entirely theatrical moral posturing around debates on pharmaceutical spending and pricing. The language of sin and salvation is consistently used…...

PharmaDispatch
pharmadispatch.com > news > can-glp-1s-be-more-transformative-than-ai-one-person-believe-they-already-are

Can GLP-1s be more transformative than AI - one person believes they already are - BioPharmaDispatch

3+ week, 5+ day ago   (154+ words) Can GLP-1s be more transformative than AI - one person believes they already are PharmaDispatch Can GLP-1s be more transformative than AI - one person believes they already are While Australia is debating whether to fund weight-loss medication for a group of…...

PharmaDispatch
pharmadispatch.com > news > brandon-capital-secures-landmark-novartis-acquisition-of-myricx-bio

Brandon Capital secures landmark Novartis acquisition of Myricx Bio

1+ mon, 2+ day ago   (151+ words) PharmaDispatch Brandon Capital secures landmark Novartis acquisition of Myricx Bio Australia’s largest life sciences private equity company, Brandon Capital, has announced a landmark exit as Novartis moves to acquire its portfolio company Myricx Bio in a deal valued at up…...

PharmaDispatch
pharmadispatch.com > news > ipsen-therapy-approved-in-australia-for-rare-genetic-disorder

Ipsen therapy approved in Australia for rare genetic disorder

1+ mon, 1+ week ago   (137+ words) PharmaDispatch Ipsen therapy approved in Australia for rare genetic disorder “It is wonderful to have the first treatment approved for this rare disease that significantly impacts children and their families,” said Sally Castle, CEO of the Liver Foundation. … Surely this…...

PharmaDispatch
pharmadispatch.com > news > a-comment-that-highlights-how-complexity-is-making-the-challenge-more-challenging

A comment that highlights how complexity is making the challenge more challenging

1+ mon, 1+ week ago   (163+ words) PharmaDispatch A comment that highlights how complexity is making the challenge more challenging You know we have a problem when the minister highlights as an example of the PBS ‘at its best’ a therapy that has never been evaluated for…...

PharmaDispatch
pharmadispatch.com > news > two-new-listings-add-treatment-choices-for-growth-hormone-deficiency-and-people-with-type-1-diab

Two new listings add treatment choices for growth hormone deficiency and people with type 1 diabetes

1+ mon, 1+ week ago   (133+ words) PharmaDispatch Two new listings add treatment choices for growth hormone deficiency and people with type 1 diabetes Novo Nordisk has announced that two therapies will be listed on the Pharmaceutical Benefits Scheme on 1 July, expanding subsidised options for Australians with endocrine…...

PharmaDispatch
pharmadispatch.com > news > australia-life-sciences-sector-welcomes-new-cgt-concession-and-urges-rdti-fixes

Australia's life sciences sector welcomes new CGT concession but urges RDTI fixes

1+ mon, 2+ week ago   (151+ words) PharmaDispatch Australia's life sciences sector welcomes new CGT concession but urges RDTI fixes Australia’s life sciences industry has conditionally welcomed the Albanese Government’s proposal for an Innovative Business CGT Concession, describing the move as an important recognition of the sector’s…...